Literature DB >> 15108074

Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid.

Naoyoshi Onoda1, Kana Ogisawa, Tetsuro Ishikawa, Chiemi Takenaka, Hideki Tahara, Masaaki Inaba, Tsutomu Takashima, Kosei Hirakawa.   

Abstract

PURPOSE: Telomerase activity (TA) has been extensively studied in tumors of many organs, but not the parathyroid gland. Therefore, we investigated TA in parathyroid tumors, and examined the mRNA expression of its catalytic subunits.
METHODS: We examined 17 single adenomas, one hyperplastic parathyroid gland, and one metastatic parathyroid cancer and quantified TA by fluorescence-based TRAP analysis. We also studied the expression of telomerase catalytic subunits in nine adenomas and one cancer by reverse transcription - polymerase chain reaction (RT-PCR) analysis.
RESULTS: Telomerase activity was not detected in any of the adenomas or the hyperplastic gland; however, the metastatic cancer was highly positive for TA. Both human telomerase RNA ( hTR) and human telomerase-associated pretein (hTEP-1) mRNA were detected universally in every specimen tested. Conversely, human telomerase reverse transcriptase (hTERT) mRNA was not detected by the conventional electrophoresis-based technique. Faint expression of hTERT mRNA was detected by real-time RT-PCR only in the sample of parathyroid cancer. DISCUSSION: We hypothesize that TA plays a role in the malignant transformation of parathyroid disease and suggest that hTERT mRNA expression could be the key step for TA as in other malignancies. Telomerase activity and hTERT may be useful molecular targets of parathyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15108074     DOI: 10.1007/s00595-003-2729-6

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  5 in total

Review 1.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

2.  Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.

Authors:  Peter P Truran; Sarah J Johnson; Richard D Bliss; Thomas W J Lennard; Sebastian R Aspinall
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

3.  The association between telomerase activity and expression of its RNA component (hTR) in breast cancer patients: the importance of DNase treatment.

Authors:  Saied Hosseini-Asl; Mohammad H Modarressi; Morteza Atri; Mohamed Salhab; Kefah Mokbel; Parvin Mehdipour
Journal:  J Carcinog       Date:  2006-06-02

4.  The expression of hTR and hTERT in human breast cancer: correlation with clinico-pathological parameters.

Authors:  Saied Hosseini-Asl; Morteza Atri; Mohammad H Modarressi; Mohamed Salhab; Kefah Mokbel; Parvin Mehdipour
Journal:  Int Semin Surg Oncol       Date:  2006-08-22

5.  Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers.

Authors:  Wei Guo; Jianjun Lu; Meng Dai; Taihua Wu; Zhenlong Yu; Jingshu Wang; Wangbing Chen; Dingbo Shi; Wendan Yu; Yao Xiao; Canhui Yi; Zhipeng Tang; Tingting Xu; Xiangsheng Xiao; Yuhui Yuan; Quentin Liu; Guangwei Du; Wuguo Deng
Journal:  Oncotarget       Date:  2014-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.